Tracey Mullen

Tracey Mullen is the Senior Vice President of Biopharma at Twist Bioscience. Tracey joined Twist in December of 2021 through the acquisition of Abveris, a company offering premium antibody drug discovery services to biopharma partners globally. Prior to Twist, she served as CEO of Abveris, where she managed operations and project development for both therapeutic and critical reagent in vivo antibody discovery campaigns. Before Abveris, Tracey served on the antibody discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to traditionally difficult therapeutic targets, including leveraging the Adimab platform to generate antibodies against GPCRs. Previously, she worked for a contract research organization specializing in in vivo antibody discovery. She received her B.S. in Chemical and Biological Engineering from the Massachusetts Institute of Technology and her Executive MBA from Quantic School of Business and Technology.